Dr Reddy’s Laboratories recently launched a generic version of lansoprazole delayed-release capsule used to treat heartburns and acidity in the US market. The drug was approved by the US Food and Drug Administration (USFDA) and was launched in the USA on May 18, 2012.
Lasnoprazole is the bio-equivalent version of Novartis blockbuster consumer Health’s Prevacid 24 HR capsule and it Rx-to-OTC in 2009. The Prevacid®24 HR capsule market had brand sales of approximately $115 million for the twelve months ending March 2012 according to SymphonyIRI InfoScan Reviews.
Rx-to-OTC is a process by which a drug is given FDA approval to be a drug that can be bought without prescriptions; a drug which earlier could only be obtained with a doctor’s prescription. Dr Reddy’s drug launch is a big step for Indian pharmas who are already giving big multinational companies enough heartburn with generic versions of popular drugs.